This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gillman, B. M.
Right arrow Articles by Weidanz, W. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gillman, B. M.
Right arrow Articles by Weidanz, W. P.

 Previous Article  |  Next Article 

Infection and Immunity, November 2004, p. 6359-6366, Vol. 72, No. 11
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.11.6359-6366.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Suppression of Plasmodium chabaudi Parasitemia Is Independent of the Action of Reactive Oxygen Intermediates and/or Nitric Oxide

Brad M. Gillman, Joan Batchelder, Patrick Flaherty, and William P. Weidanz*

Department of Medical Microbiology and Immunology, University of Wisconsin Medical School, Madison, Wisconsin

Received 27 May 2004/ Returned for modification 4 July 2004/ Accepted 9 August 2004


arrow
ABSTRACT
 
The killing of blood-stage malaria parasites in vivo has been attributed to reactive intermediates of oxygen (ROI) and of nitrogen (RNI). However, in the case of the latter, this contention is challenged by recent observations that parasitemia was not exacerbated in nitric oxide synthase (NOS) knockout (KO) (NOS2–/– or NOS3–/–) mice or in mice treated with NOS inhibitors. We now report that the time course shows that Plasmodium chabaudi parasitemia in NADPH oxidase KO (p47phox–/–) mice also was not exacerbated, suggesting a minimal role for ROI-mediated killing of blood-stage parasites. It is possible that the production of protective antibodies during malaria may mask the function of ROI and/or RNI. However, parasitemia in B-cell-deficient JH–/– x NOS2–/– or JH–/– x p47phox–/– mice was not exacerbated. In contrast, the magnitude of peak parasitemia was significantly enhanced in p47phox–/– mice treated with the xanthine oxidase inhibitor allopurinol, but the duration of patent parasitemia was not prolonged. Whereas the time course of parasitemia in NOS2–/– x p47phox–/– mice was nearly identical to that seen in normal control mice, allopurinol treatment of these double-KO mice also enhanced the magnitude of peak parasitemia. Thus, ROI generated via the xanthine oxidase pathway contribute to the control of ascending P. chabaudi parasitemia during acute malaria but alone are insufficient to suppress parasitemia to subpatent levels. Together, these results indicate that ROI or RNI can contribute to, but are not essential for, the suppression of parasitemia during blood-stage malaria.


arrow
INTRODUCTION
 
The adaptive immune response to blood-stage malaria parasites is dependent on both cell- and antibody-mediated immune mechanisms. Accumulating evidence indicates that activated CD4+ T cells release factors, including gamma interferon, which induce downstream mechanisms to kill parasites (reviewed in references 32, 34, and 52). Observations of fragmented DNA and condensed chromatin suggest that apoptotic and/or cytotoxic mechanisms are responsible for the killing of blood-stage malaria parasites (40). Both reactive oxygen intermediates (ROI) and reactive nitrogen intermediates (RNI), especially nitric oxide (NO), have been suggested as possible malaria-parasite-killing agents (9, 50).

Based on observations that different ROI-generating chemicals, such as tert-butyl hydroperoxide, alloxan, and phenylhydrazine, and ROI enzyme-producing substrate systems had the ability to kill murine and human malarial parasites, Clarke et al. proposed that ROI function to kill malaria parasites (9, 11). ROI are utilized in the body as oxidative, cytotoxic agents and are produced by phagocytic cells during the oxidative burst induced by infection (44). The majority of ROI, hydrogen peroxide (H2O2) or superoxide ions (O2–), are produced via two pathways, involving phagocyte NADPH oxidase or hypoxanthine metabolism (3, 24). In the phagocyte NADPH oxidase pathway, a complex of four structural proteins, flavocytochrome b558 (consisting of gp91phox and p22phox), p47phox, p67phox, and the protein encoded by rac, is required for the oxidation of O2 to H2O2 and O2– (1, 24, 31, 33, 38, 45, 55). During hypoxanthine metabolism, xanthine oxidase (XO) catalyzes the oxidation of hypoxanthine and xanthine in the presence of O2 and Fe3+ to produce uric acid, H2O2, and O2– (3, 16). Both H2O2 and O2– can function independently, as cytotoxic agents, or form other toxic molecules, including the hydroxyl radical OH–, hypochlorous acid (HOCl), and peroxynitrite (ONOO–) in the presence of NO (4).

Taylor-Robinson et al. (50) initially reported that NO killed blood-stage Plasmodium chabaudi parasites. The NO molecule is the product of a reaction involving the NO synthase (NOS) enzyme with L-arginine in the presence of oxygen (36, 37). NO is highly reactive but has a relatively short half-life under physiological conditions. Three isoforms of the NOS enzyme have been characterized based on the tissue localization of the enzyme. They include neuronal NOS, or NOS1, expressed by nerve cells during neurotransmission, inflammatory NOS, or NOS2, produced by phagocytic cells in response to pathogens, and endothelial NOS, or NOS3, produced by vascular endothelial cells to promote vasodilation (reviewed in reference 15). Because of its location in the brain parenchyma, NOS1 in all likelihood does not contribute to parasite killing during blood-stage Plasmodium infections, since the replication of these parasites is confined to the blood compartment. In addition, van der Heyde et al. (54) reported that the levels of NO found in serum during malaria could not be attributed to the function of NOS3 but instead were the product of NOS2 activation. Favre et al. (14) were the first to propose that NO does not kill blood-stage malarial parasites. Subsequent studies by others utilizing NOS2 knockout (KO) mice and NOS inhibitors reported that the time courses of parasitemia in wild-type and NOS2-deficient animals were comparable, thereby supporting the contention of Favre et al. that NO had little if any role in the elimination of blood-stage malarial parasites (54, 59).

Because NO and O2– are extremely reactive molecules, they can form ONOO– under normal physiological conditions (18, 22). Unlike NO, which has antioxidant, anti-inflammatory, and tissue-protective properties, ONOO– is capable of damaging lipids (42), proteins (23, 28), and nucleic acids (28) while producing redox-induced apoptosis (56), or ONOO– can protonate to generate OH• and nitrogen dioxide radicals (.NO2), both more reactive than the peroxynitrite precursors (4). Peroxynitrite has a critical role in the immune mechanism against numerous pathogens. Not only is ONOO– necessary for the killing of Mycoplasma pulmonis and Rhodococcus equi (12, 20), but it is also toxic to many different organisms, including Trypanosoma and Salmonella spp., most of which have generated defense mechanisms to nullify the toxic effect of ONOO– (7, 51). Although the effect of ONOO– on blood-stage malaria parasites is unknown, Pino et al. (41) have recently suggested that ONOO– may play a role in the pathogenesis of cerebral malaria by inducing apoptosis of endothelial cells.

The issue of compensation, i.e., the parasite-killing function of ROI in place of RNI and vice versa, has not been addressed in previous studies which have focused on the activities of either ROI or RNI alone. Likewise, the possibility of protective antibodies masking RNI and/or ROI antiparasitic activity has been only partially addressed in the studies of van der Heyde et al. (54), who reported that the time course of P. chabaudi parasitemia was nearly identical in knockout mice deficient in both B cells and NOS2 and in B-cell-deficient control mice. We have now examined the ability of both B-cell-intact and -deficient mice with genetic mutations of the NOS2, p47phox, or both NOS2 and p47phox genes to suppress acute P. chabaudi adami infections. We also examined the ability of mice treated with either aminoguanidine hemisulfate (AG) or allopurinol, known NO or XO inhibitors, respectively, to clear acute infection. Our findings indicate that neither ROI, NO, or ONOO– has an essential role in antibody- or cell-mediated immunity resulting in the destruction of blood-stage malaria parasites.


arrow
MATERIALS AND METHODS
 
Mice. The original breeding stock of p47phox–/– mice was a gift from Steven Holland (National Institutes of Health, Bethesda, Md.). The p47phox–/– mouse, lacking the cytosolic p47phox peptide, fails to activate phagocytic NADPH oxidase, preventing the production of ROI in phagocytic cells (25, 26). Breeding pairs of NOS2–/– mice and C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, Maine). NOS2–/– mice lack the ability to activate inflammatory nitric oxide synthase, which is responsible for the production of NO by cells of the immune system, primarily macrophages and neutrophils (30, 49). The original breeding stock of B-cell-deficient, JH–/–, mice was kindly provided by Dennis Huszar (Gen Pharm International, Mountain View, Calif.). JH–/– mice have immunoglobulin JH gene segment deletions which prevent B-cell differentiation beyond the CD43+ precursor stage (8). With the exception of JH–/– mice, which were on a 129/C57BL/6 background, all knockout mice have been backcrossed to C57BL/6 mice for at least 12 generations. Mice of both sexes, 6 to 12 weeks of age, were used in the experiments. All animals were housed, bred, and cared for by the Animal Care Unit at the University of Wisconsin Medical Sciences Center (Madison, Wisc.).

Double-KO mice, lacking both NOS2 and p47phox functional genes, were produced by mating p47phox–/– and NOS2–/– mice. The F1 progeny were then mated with parental p47phox–/– mice. The F2 progeny were genotyped by using primers and conditions described previously, and mice homozygous for the mutated p47phox gene and hemizygous for the NOS2 gene were mated (26, 57). The genotype of the resulting F3 progeny was determined by PCR to obtain mice homozygous for both the p47phox and NOS2 mutant genes (26, 30). Other double-KO mice, JH–/– x p47phox–/– and JH–/– x NOS2–/–, were produced following the same breeding scheme. Genotyping of these mice was achieved by PCR analysis, utilizing primers and conditions described previously (8, 26, 30, 57).

Parasites and infection of mice. The malarial parasite P. chabaudi adami 556 KA, referred to as P. chabaudi, was maintained as frozen stabilate material and used as previously described (21). Inoculum for the experimental animals was obtained from a BALB/c source mouse that was injected intraperitoneally (i.p.) with thawed stabilate material. Age- and sex-matched experimental and control mice were infected i.p. with 106 parasitized erythrocytes or intravenously (i.v.) with 105 parasitized erythrocytes as noted. Parasitemia was estimated by enumerating between 200 and 1,000 erythrocytes on Giemsa-stained thin blood films beginning on day 5 postinoculation (PI) and every other day thereafter until the completion of the experiment. The percent parasitemia was calculated as follows: % parasitemia = (number of parasitized erythrocytes/total number of erythrocytes) x 100.

Allopurinol treatment. To inhibit XO, experimental mice were injected daily via oral gavage with allopurinol (Sigma-Aldrich, St. Louis, Mo.) at a dose of 0.5 mg/kg of body weight suspended in 0.5 ml of dry milk reconstituted with 0.1% (wt/vol) phosphate-buffered saline (PBS), pH 7.4, as previously described by Segal et al. (47). Control mice were administered 0.5 ml of dry milk reconstituted with PBS via oral gavage. The solutions were prepared immediately prior to administration.

NOS inhibition. Mice were injected i.p. with AG (Sigma-Aldrich), a nonspecific NOS inhibitor, to prevent the production of NO. Experimental mice were treated twice daily with 5 mg of AG reconstituted in 0.2 ml of PBS (pH 7.4) per mouse; the solution was prepared immediately before injection (5). Control mice were injected with 0.2 ml of PBS.

Statistical analysis. Statistical analysis was performed with the unpaired, two-tailed, Student's t test and GraphPad Prism3 software. A P value of <0.05 was considered statistically significant.


arrow
RESULTS
 
Time course of P. chabaudi infection in p47phox–/– and NOS2–/– mice. To assess whether ROI produced via the NADPH oxidase pathway are essential in the clearance of P. chabaudi blood-stage parasites, we examined the time course of the parasitemia in p47phox–/– mice compared to that in C57BL/6 mice (Fig. 1A). Parasitemia in experimental and control groups followed a similar time course, reaching a peak level on day 7 and declining to subpatent levels at approximately 3 weeks PI. At the peak, the mean parasitemia percentages in p47phox–/– and control mice were similar, being 7.13 ± 3.90% and 3.45 ± 3.28%, respectively.



View larger version (15K):
[in this window]
[in a new window]
  		FIG. 1. The time courses of parasitemia in p47phox KO (n = 8) and control (n = 6) mice (panel A) and in NOS2 KO (n = 6) and control (n = 5) mice (panel B) infected with 106 P. chabaudi-parasitized erythrocytes. Data represent the mean (± standard deviation [SD]) parasitemia for each time point. These experiments were repeated twice with similar results.

To determine whether NO produced by inducible NOS is vital for the clearance of P. chabaudi during blood-stage infection, the time courses of infection in NOS2–/– and C57BL/6 mice were compared (Fig. 1B). Parasitemia in experimental and control groups peaked on day 9 (6.32 ± 4.62% and 8.88 ± 1.68%, respectively) and declined to subpatent levels by day 20 PI; the time course of infection was similar for both groups. Differences in experimental and control mean parasitemia values were statistically significant (P = 0.003) only on day 13 PI, when the parasitemia in control mice exceeded that in NOS2–/– mice.

P. chabaudi parasitemia in p47phox–/– x NOS2–/– mice. To address the possibility that ROI and NO function in a redundant fashion to suppress P. chabaudi parasites, the time courses of infections were monitored in groups of double-KO (p47phox–/– x NOS2–/–) and control (p47phox+/– x NOS2–/–) mice (Fig. 2A). Peak parasitemia was achieved on day 7 in both groups of mice, with the mean parasitemia reaching 4.90 ± 3.87% and 6.42 ± 0.93% for experimental and control groups, respectively; by 3 weeks PI, parasitemia became undetectable.



View larger version (14K):
[in this window]
[in a new window]
  		FIG. 2. The time courses of parasitemia in p47phox–/– x NOS2–/– double-KO (n = 6) and control (n = 4) mice infected i.p. with 106 P. chabaudi-infected erythrocytes (panel A) and in p47phox KO mice treated with aminoguanidine (n = 4) or phosphate-buffered saline (n = 3) and infected i.v. with 105 P. chabaudi-parasitized erythrocytes (panel B). Data represent the mean (± SD) parasitemia for each time point. These experiments were repeated twice with similar results.

Because NO is also produced by other isoforms of the nitric oxide synthase enzyme, p47phox–/– mice were infected i.v. with 105 P. chabaudi parasites and treated with the nonspecific NOS inhibitor, AG, or PBS (Fig. 2B). Parasitemia in treated and control mice followed a similar time course, reaching a peak on day 7 (23.59 ± 1.50% and 24.23 ± 4.10%, respectively) and declining to <0.01% by 3 weeks PI.

Time course of P. chabaudi parasitemia in B-cell-deficient p47phox–/– or NOS2–/– mice. To address the possibility that antibodies mask the putative function of ROI and NO against malaria parasites in wild-type mice, we produced double-KO mice deficient in B cells and either NADPH oxidase or NOS2 as described above. Groups of JH–/– x p47phox–/– and control JH–/– x p47phox+/– mice were inoculated with 106 parasitized erythrocytes, and the subsequent time course of the infection was followed. The results (Fig. 3A) indicate that parasitemia in both the experimental and control groups reached peak values (8.41 ± 3.30% and 9.29 ± 5.63%, respectively) (P = 0.736) on day 9 PI and declined to <0.1% by day 19 PI.



View larger version (16K):
[in this window]
[in a new window]
  		FIG. 3. The time courses of parasitemia in B-cell-deficient p47phox KO (n = 7) versus control (n = 5) mice (panel A) and B-cell-deficient NOS2 KO (n = 5) versus control (n = 5) mice (panel B) infected i.p. with 106 parasitized erythrocytes. Data represent the mean (± SD) parasitemia for each time point. These experiments were repeated twice with similar results.

The time course of P. chabaudi infection was also examined in JH–/– x NOS2–/– mice to determine whether NOS2 was essential for the suppression of parasitemia in the absence of B cells. The time courses of infection in JH–/– x NOS2–/– and JH–/– x NOS2+/– mice were nearly identical (Fig. 3B). Parasitemia in mice from both the double-KO and control groups reached a peak (17.50 ± 3.49% and 12.86 ± 7.87%, respectively) (P = 0.263) on day 9 PI and declined to undetectable levels by 3 weeks PI.

Time course of P. chabaudi parasitemia in p47phox–/– mice treated with allopurinol. To determine whether XO functions in a redundant fashion, producing ROI to suppress parasitemia when the NADPH oxidase pathway is absent, we compared P. chabaudi parasitemia in p47phox–/– mice treated with allopurinol in skim milk versus control p47phox–/– mice treated with skim milk alone (Fig. 4A). The peak parasitemia in experimental mice was twofold greater than that observed in control mice, 35.96 ± 12.79% compared to 14.41 ± 9.71%, on day 7 PI. Subsequently, parasitemia followed an identical time course in both groups, declining to subpatent levels by day 21 PI.



View larger version (14K):
[in this window]
[in a new window]
  		FIG. 4. The time courses of parasitemia in p47phox KO mice treated with allopurinol (Allo) (n = 3) versus p47phox KO control mice (Con) (n = 3) (panel A), NOS2 KO mice treated with allopurinol (n = 9) versus NOS2 KO control mice (n = 7) (panel B), and p47phox–/– x NOS2–/– mice treated with allopurinol (n = 5) versus p47phox–/– x NOS2–/– control mice (n = 3) (panel C) infected i.p. with 106 parasitized erythrocytes. Data represent the mean (± SD) parasitemia for each time point. These experiments were repeated twice with similar results.

Time course of P. chabaudi infection in NOS2–/– mice treated with allopurinol. Because ROI are also produced via the XO pathway, we treated NOS2–/– mice with the XO inhibitor allopurinol to determine whether ROI were produced by XO function in conjunction with NO to suppress parasitemia (Fig. 4B). At the peak, day 7 PI, the NOS2–/– mice treated with allopurinol had a parasitemia percentage (25.76 ± 10.79%) nearly three times greater than the untreated NOS2–/– control mice (8.18 ± 4.33%). By day 13 PI, both the experimental and control groups had similar levels of parasitemia; the subsequent suppression of parasitemia in both groups followed a similar time course, with parasitemia becoming undetectable by day 19 PI.

Time course of P. chabaudi parasitemia in p47phox–/– x NOS2–/– mice treated with allopurinol. As indicated above, ROI are produced by two pathways, the XO and NADPH oxidase pathways. To exclude the possibility that these potentially redundant pathways are functioning independently or in conjunction with NO to suppress parasitemia, we examined the time course of P. chabaudi in p47phox–/– x NOS2–/– mice treated with allopurinol versus that in controls treated with skim milk (Fig. 4C). Similar to the results observed in single-KO mice treated with allopurinol, the p47phox–/– x NOS2–/– double-KO mice treated with allopurinol had a twofold increase in parasitemia (19.15 ± 9.68%) compared to the control group (9.27 ± 3.06%) during the peak, but the two groups did not differ in the subsequent course of infection. By day 13 PI, the parasitemia percentages in both groups were similar, and parasites were undetectable by 3 weeks PI.

P. chabaudi infection in JH–/– x p47phox–/– and JH–/– x NOS2–/– mice treated with allopurinol. To determine whether the possible loss of parasite-killing function in p47phox–/– mice treated with allopurinol was masked by antibodies, we assessed the time course of P. chabaudi parasitemia in B-cell-deficient p47phox–/– mice treated with allopurinol (Fig. 5A). During peak infection on day 7 PI, JH–/– x p47phox–/– mice treated with allopurinol had nearly four times the number of infected erythrocytes (30.53 ± 10.84%) compared to the controls treated with skim milk (8.84 ± 9.84%). However, by day 13 PI, declining parasitemia in both groups was similar, and both groups followed a similar time course until suppression of the acute infection on day 21 PI.



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 5. The time courses of parasitemia in B-cell-deficient p47phox KO mice treated with allopurinol (Allo) (n = 4) versus B-cell-deficient p47phox KO control mice (Con) (n = 3) (panel A) and B-cell-deficient NOS2 KO mice treated with allopurinol (n = 14) versus B-cell-deficient NOS2 KO control mice (n = 7) (panel B) infected i.p. with 106 parasitized erythrocytes. Data represent the mean (± SD) parasitemia for each time point. These experiments were repeated twice with similar results.

Similarly, to exclude the possibility that the parasite-suppressive function of ROI produced via XO in conjunction with NO was masked by antibodies, we injected JH–/– x NOS2–/– mice with 106 parasitized erythrocytes i.p. and treated groups with either allopurinol or skim milk (Fig. 5B). JH–/– x NOS2–/– mice had a twofold increase in parasitemia over untreated control animals during the peak of infection on day 7 PI (34.90 ± 8.13% versus 17.36 ± 7.92%). By day 13 PI, the declining parasitemia in both groups of mice was similar and remained so through resolution of the acute infection on day 21 PI.

Summary of results. The salient features of the parasitemia data are summarized in Table 1.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Summary of data on parasitemia in the different mouse models at three time points during infectiona


arrow
DISCUSSION
 
The immune mechanisms by which the host eliminates blood-stage malaria parasites remain to be elucidated. Although both innate and adaptive mechanisms of immunity appear to be involved, how they function needs further clarification. Among the innate immune mechanisms that have been proposed to kill malaria parasites are those mediated by ROI and RNI, especially NO and ONOO–, both generated early during infection prior to the activation of adaptive immune mechanisms and later as components of the effector arm of the adaptive immune response (9, 17, 50). However, data supporting a parasite-killing role for these molecules have often been conflicting, especially when results from in vitro and in vivo studies have been compared (reviewed in reference 34). The current thinking is that these molecules have important immunoregulatory roles and are directly involved in the pathogenesis of malaria (reviewed in reference 34). For example, NO has been reported to down-regulate the production of proinflammatory cytokines, including tumor necrosis factor alpha and interleukin-1, which contribute to the pathology of disease (reviewed in reference 34).

In our initial studies, we examined the course of P. chabaudi parasitemia in NOS2–/– and p47phox–/– mice. Our data indicate that the time courses of infection in both KO mice and their respective controls were nearly identical, suggesting that neither RNI nor ROI are essential for the elimination of blood-stage malaria parasites. Similar results were obtained when these KO mice were infected with the avirulent 17X strain of Plasmodium yoelii, i.e., the time course of parasitemia was nearly identical in KO and control mice (B. M. Gillman, unpublished observations). These observations are in agreement with those of others who reported that P. chabaudi parasitemia in NOS2–/– and control mice was nearly identical (14, 54, 59).

To our knowledge, malaria has not been studied previously in the p47phox–/– mouse model. Sanni et al. (46), who followed lethal Plasmodium berghei infections in gp91phox–/– mice, which also failed to produce ROI via NADPH oxidase, reported that parasitemia was significantly enhanced in the KO mice compared to that in controls. This observation, in contrast to our findings, suggests that ROI generated via NADPH oxidase does kill blood-stage malaria parasites. A possible explanation for the discrepancies between our findings and those of Sanni et al. is that these Plasmodium parasites differ in their susceptibility to the action of ROI, with P. yoelii and P. chabaudi being more resistant than P. berghei. To conclude from our studies and from those of others that RNI and ROI are incapable of killing blood-stage malarial parasites may be premature for several reasons: (i) the in vivo ability to kill malaria parasites may be masked by the antibody response of the infected host, and (ii) the killing mechanisms mediated by these molecules may function in a redundant fashion.

Previously, we reported a plasticity in the adaptive immune responses that eliminate blood-stage malaria parasites (57), i.e., mice can suppress parasitemia by either antibody-mediated immunity or T-cell-dependent cell-mediated immunity. The cell-mediated immune response precedes the antibody response, which subsequently down-regulates the cell-mediated immune response. A plausible explanation for the results seen in our experiments with single-KO mice is that a similar phenomenon was occurring, in that the developing antibody response suppressed parasitemia and obscured our ability to determine whether ROI or RNI were critical for parasite elimination. However, we observed that P. chabaudi parasitemia followed a nearly identical time course in B-cell-deficient NOS2–/– or B-cell-deficient p47phox–/– mice and their respective controls. These results exclude the possibility that antibodies were masking the putative function of ROI and/or RNI in the elimination of blood-stage parasites.

Redundancies in the NO-producing machinery of the host might help to explain why parasitemia was unaffected by the deletion of the NOS2 gene in our studies. Of the three NOS isoforms which are known to generate NO, only NOS2 and NOS3 contribute to blood levels of RNI (27). Thus, nitric oxide sufficient to kill blood-stage parasites may have been produced via NOS3 in NOS2–/– mice infected with P. chabaudi; however, the findings of van der Heyde et al. (54) argue against this contention. van der Heyde et al. found that P. chabaudi parasitemia followed an identical time course in NOS3–/– mice and their controls and concluded from their studies that most of the NO in blood during P. chabaudi malaria was the product of NOS2 activity. Our observation that P. chabaudi followed the same time course in p47phox–/– mice treated with the nonspecific NOS inhibitor, AG, are in agreement with the concept that other isoforms of NOS do not function to produce parasite-killing levels of RNI in NOS2–/– mice. Similar results were obtained when JH–/– x NOS2–/– mice were treated with N(G)-monomethyl-L-arginine (Gillman, unpublished).

It is also possible that ROI may compensate for the loss of RNI, or vice versa, during P. chabaudi infection. To examine this possible redundancy between reactive intermediate systems, we assessed parasitemia in p47phox–/– x NOS2–/– double-KO mice. When double-KO mice were infected with P. chabaudi, the resulting time course of infection was nearly identical to that of control mice. These data suggest that the production of RNI in place of ROI, or ROI in place of RNI, was not responsible for the killing of parasites in single-KO (p47phox–/– or NOS2–/–) mice.

As indicated earlier, ROI are produced via two metabolic pathways, involving either NADPH oxidase or XO. It is possible that a redundancy involving these mechanisms could produce ROI in the absence of either enzyme and explain the ability for p47phox–/– mice to suppress parasitemia in a normal time frame. When p47phox–/– mice were treated with the XO inhibitor allopurinol and infected with P. chabaudi, the magnitude of peak parasitemia was more than twice that seen in control mice. When allopurinol was used to treat NOS2–/– mice, we observed similar results, i.e., peak parasitemia increased over twofold compared to controls. These data suggest that ROI produced via the XO enzyme, in contrast to NADPH oxidase, are capable of modulating parasitemia.

Büngener, in the mid-1970s, also reported that infections induced with different malaria parasites, including P. chabaudi, were exacerbated by allopurinol treatment (6). He interpreted his results as being due to an increase in the multiplication of parasites in allopurinol-treated mice. Allopurinol inhibits XO, which normally metabolizes hypoxanthine to xanthine and uric acid, and allows hypoxanthine to accumulate in the blood of the infected host, thereby stimulating parasite growth (60). Subsequently, allopurinol was observed to inhibit the production of ROI by XO, which has been reported to increase in phagocytic cells during the course of malaria (53). Inspection of thin blood films prepared from allopurinol-treated mice and controls failed to reveal differences in parasite life cycle stages between treated and untreated mice (Gillman, unpublished).

When B-cell-deficient p47phox–/– mice or B-cell-deficient NOS2–/– mice were treated with allopurinol and infected with P. chabaudi, the peak levels of parasitemia were significantly higher during infection than those in control mice. Parasitemia profiles in P. chabaudi-infected p47phox–/– x NOS2–/– mice treated with allopurinol were similar to those reported for other allopurinol-treated mice, i.e., peak levels of parasitemia were two- to threefold greater than those seen in untreated p47phox–/– x NOS2–/– control mice. Collectively, our findings suggest that ROI produced early during P. chabaudi infection, via the XO pathway, function to modulate parasitemia but are unable to suppress parasitemia to subpatent levels. Previous observations support the contention that JH–/– x {delta}–/– mice, in which ROI-generating mechanisms presumably are intact, lack cell-mediated immunity against blood-stage P. chabaudi parasites and consequently develop unremitting parasitemia (59). The different effects on parasitemia observed when the XO pathway versus the NADPH oxidase pathway of ROI production was blocked may be due to differences in the amounts of ROI produced by each pathway. Our findings are in agreement with those of others who reported that molecules capable of causing oxidant stress leading to lipid peroxidation in erythrocytes in vivo down-modulated parasitemia but did not sterilize infection (reviewed in reference 10).

Although both RNI and ROI have been reported to kill Plasmodium falciparum as well as murine malaria parasites in vitro (29, 35, 43), it has been difficult to directly assess their function in vivo (19, 39). ROI generated by the action of glucose oxidase or xanthine oxidase on their respective substrates were reported to kill P. falciparum and P. yoelii in vitro (13, 58). Likewise, RNI induced by various agents were observed to be toxic and/or cytostatic for P. falciparum and several murine malaria parasites (2). These cumulative data suggest differences in the susceptibilities to both ROI and RNI between parasite species. In vivo, these radicals are short lived, being scavenged by replenishing molecules of both host and parasite origin, whereas in vitro, the radicals are also short lived but the environment is static. In addition, relatively few target parasites are added to the culture dishes in contrast to the very large number of parasites circulating in the blood of the infected host. Studies in humans have been primarily correlative, suggesting that these reactive intermediates may be involved in the killing of parasites and the pathogenesis of malaria. The use of KO mouse models in our studies has allowed us to test directly whether RNI and/or ROI play an essential role in the suppression of parasitemia.

Based on the similarities of parasitemia curves in p47phox–/– and NOS2–/– mice and their respective controls, we conclude that ROI and RNI, including NO and ONOO–, produced via the activity of the enzymes are not essential for the elimination of blood-stage P. chabaudi parasites. We speculate that ROI represent an early response to blood-stage parasites that is aimed at slowing the rate of ascending parasitemia as other elements of innate immunity are being activated. For example, it is now established that NK cells are also activated early during infection by parasite products via pattern recognition mechanisms (48). These cells secrete gamma interferon, which stimulates phagocytic cells to produce ROI, RNI, proinflammatory cytokines, and chemokines, elements that contribute to the activation and regulation of the adaptive immune responses which sterilize infection (48).


arrow
ACKNOWLEDGMENTS
 
We thank GayeLyn LaFleur for her technical assistance, Vielska Brautigam, Erin Peterson, and Josh Blomberg for their help with these studies, and our colleague James Burns, Jr., for reviewing the manuscript.

This work was supported by NIH-NIAID grant AI012710.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Medical Microbiology and Immunology, University of Wisconsin Medical School, 1300 University Ave., Madison, WI 53706. Phone: (608) 262-9027. Fax: (608) 262-8418. E-mail: wweidanz{at}wisc.edu. Back

Editor: W. A. Petri, Jr.


arrow
REFERENCES
 
    1
  1. Abo, A., E. Pick, A. Hall, N. Totty, C. G. Teahan, and A. W. Segal. 1991. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 353:668-670.[CrossRef][Medline]
    2. 2
  2. Balmer, P., H. M. Phillips, A. E. Maestre, F. A. McMonagale, and S. R. Phillips. 2000. The effect of nitric oxide on the growth of Plasmodium falciparum, P. chabaudi, and P. berghei in vitro. Parasite Immunol. 22:97-106.[CrossRef][Medline]
    3. 3
  3. Beauchamp, C., and I. Fridovich. 1970. A mechanism for the production of ethylene from methional. The generation of the hydroxyl radical by xanthine oxidase. J. Biol. Chem. 245:4641-4646.[Abstract/Free Full Text]
    4. 4
  4. Beckman, J. S., T. W. Beckman, J. Chen, P. A. Marshall, and B. A. Freeman. 1990. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA 87:1620-1624.[Abstract/Free Full Text]
    5. 5
  5. Bucala, R., K. J. Tracey, and A. Cerami. 1991. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Investig. 87:432-438.
    6. 6
  6. Büngener, W. 1974. Influence of allopurinol on the multiplication of rodent malaria parasites. Tropenmed. Parasitol. 25:309-312.[Medline]
    7. 7
  7. Chakravortty, D., I. Hansen-Wester, and M. Hensel. 2002. Salmonella pathogenicity island 2 mediates protection of intracellular Salmonella from reactive nitrogen intermediates. J. Exp. Med. 195:1155-1166.[Abstract/Free Full Text]
    8. 8
  8. Chen, J., M. Trounstine, F. W. Alt, F. Young, C. Kurahara, J. F. Loring, and D. Huszar. 1993. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int. Immunol. 6:647-656.
    9. 9
  9. Clark, I. A., and N. H. Hunt. 1983. Evidence for reactive oxygen intermediates causing hemolysis and parasite death in malaria. Infect. Immun. 39:1-6.[Abstract/Free Full Text]
    10. 10
  10. Clark, I. A., N. H. Hunt, and W. B. Cowden. 1986. Oxygen-derived free radicals in the pathogenesis of parasitic disease. Adv. Parasitol. 25:1-44.[Medline]
    11. 11
  11. Clark, I. A., N. H. Hunt, W. B. Cowden, L. E. Maxwell, and E. J. Mackie. 1984. Radical-mediated damage to parasites and erythrocytes in Plasmodium vinckei infected mice after injection of t-butyl hydroperoxide. Clin. Exp. Immunol. 56:524-530.[Medline]
    12. 12
  12. Darrah, P. A., M. K. Hondalus, Q. Chen, H. Ischiropoulos, and D. M. Mosser. 2000. Cooperation between reactive oxygen and nitrogen intermediates in killing of Rhodococcus equi by activated macrophages. Infect. Immun. 68:3587-3593.[Abstract/Free Full Text]
    13. 13
  13. Dockrell, H. M., and J. H. Playfair. 1984. Killing of Plasmodium yoelii by enzyme-induced products of the oxidative burst. Infect. Immun. 43:451-456.[Abstract/Free Full Text]
    14. 14
  14. Favre, N., B. Ryffel, and W. Rudin. 1999. Parasite killing in murine malaria does not require nitric oxide production. Parasitology 118:139-143.
    15. 15
  15. Forstermann, U., J. P. Boissel, and H. Kleinert. 1998. Expressional control of the ‘constitutive’ isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J. 12:773-790.[Abstract/Free Full Text]
    16. 16
  16. Fridovich, I. 1970. Quantitative aspects of the production of superoxide anion radical by milk xanthine oxidase. J. Biol. Chem. 245:4053-4057.[Abstract/Free Full Text]
    17. 17
  17. Fritsche, G., C. Larcher, H. Schennach, and G. Weiss. 2001. Regulatory interactions between iron and nitric oxide metabolism for immune defense against Plasmodium falciparum infection. J. Infect. Dis. 183:1388-1394.[CrossRef][Medline]
    18. 18
  18. Goldstein, S., and G. Czapski. 1995. The reaction of NO. with O2– and HO2–: a pulse radiolysis study. Free Radic. Biol. Med. 19:505-510.[CrossRef][Medline]
    19. 19
  19. Greve, B., L. G. Lehman, B. Lell, D. Luckner, R. Schmidt-Ott, and P. G. Kremsner. 1999. High oxygen radical production is associated with fast parasite clearance in children with Plasmodium falciparum malaria. J. Infect. Dis. 179:1584-1586.[CrossRef][Medline]
    20. 20
  20. Hickman-Davis, J., J. Gibbs-Erwin, J. R. Lindsey, and S. Matalon. 1999. Surfactant protein A mediates mycoplasmacidal activity of alveolar macrophages by production of peroxynitrite. Proc. Natl. Acad. Sci. USA 96:4953-4958.[Abstract/Free Full Text]
    21. 21
  21. Hoffmann, E. J., W. P. Weidanz, and C. A. Long. 1984. Susceptibility of CXB recombinant inbred mice to murine plasmodia. Infect. Immun. 43:981-985.[Abstract/Free Full Text]
    22. 22
  22. Huie, R. E., and S. Padmaja. 1993. The reaction of NO with superoxide. Free Radic. Res. Commun. 18:195-199.[Medline]
    23. 23
  23. Ischiropoulos, H., L. Zhu, J. Chen, M. Tsai, J. C. Martin, C. D. Smith, and J. S. Beckman. 1992. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 298:431-437.[CrossRef][Medline]
    24. 24
  24. Iyer, G. Y. N., M. F. Islam, and J. H. Quastei. 1961. Biochemical aspects of phagocytosis. Nature 192:535-541.[CrossRef]
    25. 25
  25. Jackson, S. H., H. L. Malech, C. A. Kozak, K. J. Lomax, J. I. Gallin, and S. M. Holland. 1994. Cloning and functional expression of the mouse homologue of p47phox. Immunogenetics 39:272-275.[Medline]
    26. 26
  26. Jackson, S. H., J. I. Gallin, and S. M. Holland. 1995. The p47phox mouse knock-out model of chronic granulomatous disease. J. Exp. Med. 182:751-758.[Abstract/Free Full Text]
    27. 27
  27. Jubelin, B. C., and J. L. Gierman. 1996. Erythrocytes may synthesize their own nitric oxide. Am. J. Hypertens. 9:1214-1219.[CrossRef][Medline]
    28. 28
  28. King, P. A., V. E. Anderson, J. O. Edwards, G. Gustafson, R. C. Plumb, and J. W. Suggs. 1992. A stable solid that generates hydroxyl radical upon dissolution in aqueous solutions. Reactions with proteins and nucleic acid. J. Am. Chem. Soc. 114:5430-5432.[CrossRef]
    29. 29
  29. Kwiatkowski, D., and P. Perlmann. 1999. Inflammatory processes in the pathogenesis of malaria, p. 329-362. In M. Wahlgren and P. Perlmann (ed.), Malaria: molecular and clinical aspects. Harwood Academic Publishers, Chur, Switzerland.
    30. 30
  30. Laubach, V. E., E. G. Shesely, O. Smithies, and P. A. Sherman. 1995. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc. Natl. Acad. Sci. USA 92:10688-10692.[Abstract/Free Full Text]
    31. 31
  31. Leto, T. L., K. J. Lomax, B. D. Volpp, H. Nunoi, J. M. Sechler, W. M. Nauseef, R. A. Clark, J. I. Gallin, and H. L. Malech. 1990. Cloning of a 67-kD neutrophil oxidase factor with similarity to a noncatalytic region of p60c-src. Science 248:727-730.[Abstract/Free Full Text]
    32. 32
  32. Li, C., and J. Langhorne. 2000. Tumor necrosis factor alpha p5 receptor is important for development of memory responses to blood-stage malaria infection. Infect. Immun. 68:5724-5730.[Abstract/Free Full Text]
    33. 33
  33. Lomax, K. J., T. L. Leto, H. Nunoi, J. I. Gallin, and H. L. Malech. 1989. Recombinant 47-kilodalton cytosol factor restores NADPH oxidase in chronic granulomatous disease. Science 245:409-412.[Abstract/Free Full Text]
    34. 34
  34. Mohan, K., and M. M. Stevenson. 1998. Acquired immunity to asexual blood stages, p. 467-493. In I. W. Sherman (ed.), Malaria: parasite biology, pathogenesis, and protection. American Society for Microbiology, Washington, D.C.
    35. 35
  35. Ockenhouse, C. F., S. Schulman, and H. L. Shear. 1984. Oxidative killing of malaria parasites by mononuclear phagocytes. Prog. Clin. Biol. Res. 155:93-108.[Medline]
    36. 36
  36. Palacios, M., R. G. Knowles, R. M. Palmer, and S. Moncada. 1989. Nitric oxide from L-arginine stimulates the soluble guanylate cyclase in adrenal glands. Biochem. Biophys. Res. Commun. 165:802-809.[CrossRef][Medline]
    37. 37
  37. Palmer, R. M., D. S. Ashton, and S. Moncada. 1988. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333:664-666.[CrossRef][Medline]
    38. 38
  38. Parkos, C. A., M. C. Dinauer, L. E. Walker, R. A. Allen, A. J. Jesaitis, and S. H. Orkin. 1988. Primary structure and unique expression of the 22-kilodalton light chain of human neutrophil cytochrome b. Proc. Natl. Acad. Sci. USA 85:3319-3323.[Abstract/Free Full Text]
    39. 39
  39. Perlmann, P., and M. Troye-Blomberg. 2002. Malaria and the immune system in humans. Chem. Immunol. 80:229-242.[Medline]
    40. 40
  40. Picot, S., J. Burnod, V. Bracchi, B. F. Chumpitazi, and P. Ambroise-Thomas. 1997. Apoptosis related to chloroquine sensitivity of the human malaria parasite Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg. 91:590-591.[CrossRef][Medline]
    41. 41
  41. Pino, P., I. Vouldoukis, N. Dugas, G. Hassani-Loppion, B. Dugas, and D. Mazier. 2003. Redox-dependent apoptosis in human endothelial cells after adhesion of Plasmodium falciparum-infected erythrocytes. Ann. N. Y. Acad. Sci. 1010:582-586.[CrossRef][Medline]
    42. 42
  42. Radi, R., J. S. Beckman, K. M. Bush, and B. A. Freeman. 1991. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch. Biochem. Biophys. 288:481-487.[CrossRef][Medline]
    43. 43
  43. Rockett, K. A., M. M. Awburn, W. B. Cowden, and I. A. Clark. 1991. Killing of Plasmodium falciparum in vitro by nitric oxide derivatives. Infect. Immun. 59:3280-3283.[Abstract/Free Full Text]
    44. 44
  44. Rossi, F., D. Romeo, and P. Patriarca. 1976. Metabolic perturbation of the inflammatory cells. Agents Actions 6:50-59.[CrossRef][Medline]
    45. 45
  45. Royer-Pokora, B., L. M. Kunkel, A. P. Monaco, S. C. Goff, P. E. Newburger, R. L. Baehner, F. S. Cole, J. T. Curnutte, and S. H. Orkin. 1986. Cloning the gene for an inherited human disorder-chronic granulomatous disease-on the basis of its chromosomal location. Nature 322:32-38.[CrossRef][Medline]
    46. 46
  46. Sanni, L. A., S. Fu, R. T. Dean, G. Bloomfield, R. Stocker, G. Chaudhri, M. C. Dinauer, and N. H. Hunt. 1999. Are reactive oxygen species involved in the pathogenesis of murine cerebral malaria? J. Infect. Dis. 179:217-222.[CrossRef][Medline]
    47. 47
  47. Segal, B. H., N. Sakamoto, M. Patel, K. Maemura, A. S. Klein, S. M. Holland, and G. B. Bulkley. 2000. Xanthine oxidase contributes to host defense against Burkholderia cepacia in the p47phox–/– mouse model of chronic granulomatous disease. Infect. Immun. 68:2374-2378.[Abstract/Free Full Text]
    48. 48
  48. Stevenson, M. M., and E. M. Riley. 2004. Innate immunity to malaria. Nat. Rev. Immunol. 4:169-180.[CrossRef][Medline]
    49. 49
  49. Stuehr, D. J., S. S. Gross, I. Sakuma, R. Levi, and C. F. Nathan. 1989. Activated murine macrophages secrete a metabolite of arginine with the bioactivity of endothelium-derived relaxing factor and the chemical reactivity of nitric oxide. J. Exp. Med. 3:1011-1020.
    50. 50
  50. Taylor-Robinson, A. W., R. S. Phillips, A. Severn, S. Moncada, and F. Y. Liew. 1993. The role of TH1 and TH2 cells in a rodent malaria infection. Science 260:1931-1934.[Abstract/Free Full Text]
    51. 51
  51. Thomson, L., A. Denicola, and R. Radi. 2003. The trypanothione-thiol system in Trypanosoma cruzi as a key antioxidant mechanism against peroxynitrite-mediated cytotoxicity. Arch. Biochem. Biophys. 412:55-64.[CrossRef][Medline]
    52. 52
  52. Troye-Blomberg, M., W. P. Weidanz, and H. C. van der Heyde. 1999. The role of T cells in immunity to malaria and the pathogenesis of disease, p. 403-438. In M. Wahlgren and P. Perlmann (ed.), Malaria: molecular and clinical aspects. Harwood Academic Publishers, Reading, United Kingdom.
    53. 53
  53. Tubaro, E., B. Lotti, C. Santiangeli, and G. Cavallo. 1980. Xanthine oxidase increase in polymorphonuclear leucocytes and macrophages in mice in three pathological situations. Biochem. Pharmacol. 29:1945-1948.[CrossRef][Medline]
    54. 54
  54. van der Heyde, H. C., Y. Gu, Q. Zhang, G. Sun, and M. B. Grisham. 2000. Nitric oxide is neither necessary nor sufficient for resolution of Plasmodium chabaudi malaria in mice. J. Immunol. 165:3317-3323.[Abstract/Free Full Text]
    55. 55
  55. Volpp, B. D., W. M. Nauseef, J. E. Donelson, D. R. Moser, and R. A. Clark. 1989. Cloning of the cDNA and functional expression of the 47-kilodalton cytosolic component of human neutrophil respiratory burst oxidase. Proc. Natl. Acad. Sci. USA 86:7195-7199.[Abstract/Free Full Text]
    56. 56
  56. Vouldoukis, I., V. Sivan, M. C. Vozenin, C. Kamate, A. Calenda, D. Mazier, and B. Dugas. 2000. Fc-receptor-mediated intracellular delivery of Cu/Zn-superoxide dismutase (SOD1) protects against redox-induced apoptosis through a nitric oxide dependent mechanism. Mol. Med. 6:1042-1053.[Medline]
    57. 57
  57. Weidanz, W. P., J. R. Kemp, J. M. Batchelder, F. K. Cigel, M. Sandor, and H. C. van der Heyde. 1999. Plasticity of immune responses suppressing parasitemia during acute Plasmodium chabaudi malaria. J. Immunol. 162:7383-7388.[Abstract/Free Full Text]
    58. 58
  58. Wozencraft, A. O., H. M. Dockrell, J. Taverne, G. A. Targett, and J. H. Playfair. 1984. Killing of human malaria parasites by macrophage secretory products. Infect. Immun. 43:664-669.[Abstract/Free Full Text]
    59. 59
  59. Yoneto, T., T. Yoshimoto, C.-R. Wang, Y. Takahama, M. Tsuji, S. Waki, and H. Nariuchi. 1999. Gamma interferon production is critical for protective immunity to infection with blood-stage Plasmodium berghei XAT but neither NO production nor NK cell activation is critical. Infect. Immun. 67:2349-2356.[Abstract/Free Full Text]
    60. 60
  60. Yue, T. F., and A. B. Gutman. 1964. Effect of allopurinol (4-hydroxypyrazolo-(3,4-D)pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am. J. Med. 37:885-898.

Infection and Immunity, November 2004, p. 6359-6366, Vol. 72, No. 11
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.11.6359-6366.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gillman, B. M.
Right arrow Articles by Weidanz, W. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gillman, B. M.
Right arrow Articles by Weidanz, W. P.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»